PCCA/ANNA by IFA with Reflex to Titer and Immunoblot
Aid in the diagnosis of paraneoplastic neurologic syndromes associated with malignancy. Order based on clinical presentation.
Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot
Sun, Wed, Fri
New York DOH Approval Status
Serum separator tube
Separate serum from cells ASAP or within 2 hours of collection. Transfer 2 mL serum to an ARUP Standard Transport Tube. (Min: 0.75 mL)
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
After separation from cells: Ambient: 24 hours; Refrigerated: 2 weeks; Frozen: 1 year
|Purkinje Cell/Neuronal Nuclear IgG Scrn||None Detected|
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Purkinje Cell (PCCA) antibody and Neuronal Nuclear (ANNA) antibody IgG are screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu, Ri, Yo, and Tr/DNER) IgG by Immunoblot will be added. If the IFA screen is positive at 1:10 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, and Tr/DNER) IgG by Immunoblot will be added. Additional charges apply.
86255; if reflexed add 84182 x4 and/or 86256
|Component Test Code*||Component Chart Name||LOINC|
|2007962||Purkinje Cell/Neuronal Nuclear IgG Scrn||61177-2|
- Anti Ri
- Antinuclear neuronal Ab
- Neuronal Nuclear Antibody
- Paraneoplastic Ab screen
- Paraneoplastic Autoantibody Immunoblot Confirmation, Paraneoplastic Neurological Autoimmunity
- Purkinje Cell Cytoplasmic Antibodies